Curanex Pharmaceuticals Inc (CURX)

NCM – Real vaqt narxi. Valyuta: USD

0.28

-0.06 (-16.42%)

Yopilishda: Jun 18, 2026, 4:00 PM EDT

0.28

+0.00 (1.79%)

Bozordan keyin: Jun 18, 2026, 7:54 PM EDT

22.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK, May 22, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) (the "Company" or "Curanex"). The investigation concerns whether Curanex and certain officers and/or directors have engaged in securities fraud or other unlawful business practices.

18.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK, May 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) (the "Company" or "Curanex"). The investigation concerns whether Curanex and certain officers and/or directors have engaged in securities fraud or other unlawful business practices.

14.05.2026

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company's lead drug candidate. Curanex is advancing Phyto-N toward a planned Investigational New Drug (“IND”) submission to the U.S. Food and Drug Administration (“FDA”) for ulcerative colitis in the fourth quarter of 2026.

12.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK, May 12, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) (the "Company" or "Curanex"). The investigation concerns whether Curanex and certain officers and/or directors have engaged in securities fraud or other unlawful business practices.

17.04.2026

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) resulting from allegations that Curanex may have issued materially misleading business information to the investing public. So what: If you purchased Curanex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr.

16.04.2026

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

08.04.2026

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease

Videolar

No Data

There is no data to display

Press-relizlar

22.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

18.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

14.05.2026

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

12.05.2026

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Pharmaceuticals Inc (CURX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Curanex Pharmaceuticals Inc (CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Videolar

No Data

Press-relizlar

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Videolar

No Data

Press-relizlar

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Search stocks

Curanex Pharmaceuticals Inc (CURX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Curanex Pharmaceuticals Inc (CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Videolar

No Data

Press-relizlar

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Videolar

No Data

Press-relizlar

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)